Vivos Therapeutics (VVOS) Gross Margin (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Gross Margin data on file, last reported at 59.5% in Q1 2026.

• On a quarterly basis, Gross Margin rose 947.0% year-over-year to 59.5% in Q1 2026; TTM through Mar 2026 was 61.8%, a 308.0% increase from a year earlier, with the FY2025 full-year figure at 60.44%, up 43.0% from the prior year.
• Gross Margin for Q1 2026 stood at 59.5%, down from 78.14% in the prior quarter.
• Over the last five years, Gross Margin for VVOS reached as high as 78.14% in Q4 2025 and fell as low as 50.03% in Q1 2025.
• Historically, Gross Margin has averaged 60.64% across 5 years, with a median of 60.35% in 2022.
• Across the five-year window, Gross Margin slumped 1873 bps in 2022 and jumped 2143 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 60.35% in 2022, then increased by 7 bps to 64.32% in 2023, then fell by 12 bps to 56.71% in 2024, then soared by 38 bps to 78.14% in 2025, then slipped by 24 bps to 59.5% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 59.5% in Q1 2026, 78.14% in Q4 2025, and 58.04% in Q3 2025.